Unbiased Quantitative Proteomics of Organoid Models of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a lethal solid malignancy with many patients succumbing to the disease within 6 months of diagnosis. The mechanisms that underlie PDAC initiation and progression are poorly understood. Current treatment options are primarily limited to chemotherapy, which i...

Full description

Saved in:
Bibliographic Details
Published inMethods in molecular biology (Clifton, N.J.) Vol. 2823; p. 77
Main Authors Low, Ronnie Ren Jie, Fung, Ka Yee, Dagley, Laura F, Yousef, Jumana, Emery-Corbin, Samantha J, Putoczki, Tracy L
Format Journal Article
LanguageEnglish
Published United States 2024
Subjects
Animals
Biomarkers, Tumor - metabolism
Carcinoma, Pancreatic Ductal - metabolism
Carcinoma, Pancreatic Ductal - pathology
Humans
Mice
Organoids - metabolism
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - pathology
Proteome
Proteomics - methods
Model
Organoid
FACs
Pancreatic cancer
Proteomics
Online AccessGet more information

Cover

More Information
Summary:Pancreatic ductal adenocarcinoma (PDAC) is a lethal solid malignancy with many patients succumbing to the disease within 6 months of diagnosis. The mechanisms that underlie PDAC initiation and progression are poorly understood. Current treatment options are primarily limited to chemotherapy, which is often provided with palliative intent. Unfortunately, there are no robust biomarkers to guide treatment selection or monitor treatment response. This is concerning given the increasing incidence of this cancer. We and others have generated organoid models to explore the biology underlying PDAC with the goal of identifying new therapeutic targets. Here we provide protocols to generate a preclinical PDAC organoid model and methods to use these to define the proteomic landscape of this cancer.
ISSN:1940-6029
DOI:10.1007/978-1-0716-3922-1_6